|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Short-term investments | |||||||||||||||||
| Accounts receivable, net of allowance of $55 and $27, respectively | |||||||||||||||||
| Direct contracting performance year receivable | |||||||||||||||||
| ACO REACH performance year receivable | |||||||||||||||||
| Current assets of discontinued operations | |||||||||||||||||
| Discontinued Operations | |||||||||||||||||
| Total current assets of discontinued operations | |||||||||||||||||
| Current assets of held-for-sale operations (Note 15) | |||||||||||||||||
| Prepaids and other current assets | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Other assets: | |||||||||||||||||
| Long-term investments | |||||||||||||||||
| Property, equipment and capitalized software, net | |||||||||||||||||
| Goodwill | |||||||||||||||||
| Intangible assets, net | |||||||||||||||||
| Long-term assets of discontinued operations (Note 19) | |||||||||||||||||
| Discontinued Operations | |||||||||||||||||
| Total long-term assets of discontinued operations (Note 19) | |||||||||||||||||
| Other non-current assets | |||||||||||||||||
| Total other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders’ Equity (Deficit) | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Medical costs payable | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Unearned revenue | |||||||||||||||||
| Risk adjustment payable | |||||||||||||||||
| Direct contracting performance year obligation | |||||||||||||||||
| Short-term borrowings | |||||||||||||||||
| ACO REACH performance year obligation | |||||||||||||||||
| Current liabilities of discontinued operations | |||||||||||||||||
| Discontinued Operations | |||||||||||||||||
| Disposal Group, Held-for-Sale, Not Discontinued Operations | |||||||||||||||||
| Total current liabilities of discontinued operations | |||||||||||||||||
| Risk share payable to deconsolidated entity | |||||||||||||||||
| Warrant liability | |||||||||||||||||
| Other current liabilities | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Long-term borrowings | |||||||||||||||||
| Total long-term borrowings | |||||||||||||||||
| Other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Redeemable noncontrolling interests | |||||||||||||||||
| Redeemable Series A and B preferred stock | |||||||||||||||||
| Series A preferred stock dividend accrued | |||||||||||||||||
| Series B preferred stock dividend accrued | |||||||||||||||||
| Total redeemable Series A and B preferred stock | |||||||||||||||||
| Shareholders’ equity (deficit): | |||||||||||||||||
| Common stock, $0.0001 par value; $3,000,000,000 shares authorized in 2025 and 2024; $9,024,240 and $8,320,959 shares issued and outstanding in 2025 and 2024, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Treasury stock, at cost, 2,522,148 shares at September 30, 2022 and December 31, 2021, respectively | |||||||||||||||||
| Treasury Stock, at cost, $31,526 shares at June 30, 2025, and December 31, 2024, respectively | |||||||||||||||||
| Total shareholders’ equity (deficit) | |||||||||||||||||
| Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit) | |||||||||||||||||
| Common stock, shares authorized (in shares) |
Loading...
